Imunon (NASDAQ:IMNN) Receives Buy Rating from D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $29.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Imunon in a research note on Thursday, December 19th.

Imunon Stock Up 0.1 %

Shares of NASDAQ IMNN traded up $0.00 during midday trading on Wednesday, reaching $0.86. The company had a trading volume of 572,821 shares, compared to its average volume of 149,717. Imunon has a one year low of $0.51 and a one year high of $3.65. The firm’s fifty day moving average price is $0.89 and its 200-day moving average price is $0.96. The stock has a market cap of $12.51 million, a PE ratio of -0.45 and a beta of 2.03.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC raised its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the period. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. 4.47% of the stock is owned by hedge funds and other institutional investors.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.